Comparative investigation of the anti-emetic effects of granisetron and palonosetron during the treatment of acute myeloid leukemia

  • Authors:
    • Aki Matsumaru
    • Yutaka Tsutsumi
    • Shinichi Ito
  • View Affiliations

  • Published online on: July 28, 2017     https://doi.org/10.3892/mco.2017.1350
  • Pages: 629-632
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chemotherapy-induced nausea and vomiting has a considerable negative impact on the quality of life of patients with cancer. Unfortunately, there has been little progress in the development of supportive therapies for the anti-emetic treatment of patients with hematopoietic tumors. This lack of supportive treatments motivated the present retrospective comparison between two groups of anti-emetic drugs. The current study aimed to compare granisetron and palonosetron in order to determine which is more effective, based on cases of patients undergoing remission induction therapy and consolidation therapy for the treatment of acute myeloid leukemia. Granisetron or palonosetron were administered in Japanese-approved dosages (3 mg granisetron once per day for 5 or 7 days, or one administration of 0.75 mg palonosetron). Patients were randomly selected, and their clinical information was acquired from medical records. The data represent the doctors' and nurses' records. The results demonstrated that palonosetron treatment (in which the drug was administered alone or in combination with aprepitant) was more effective than granisetron treatment for the complete control of acute vomiting. Therefore, in the treatment of hematopoietic malignancies, palonosetron is an effective regimen to be administered alongside more than 5 continuous days of anti-cancer agents. Furthermore, the combination of palonosetron and aprepitant was found to be the optimal combination. In conclusion, palonosetron is superior to granisetron for the prevention of nausea and vomiting induced by chemotherapy for hematological cancers. In Japan, the standard dose of palonosetron is 0.75 mg; a dose of 0.25 mg of palonosetron must be compared with 0.75 mg in future studies.
View Figures
View References

Related Articles

Journal Cover

October-2017
Volume 7 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Matsumaru A, Tsutsumi Y and Ito S: Comparative investigation of the anti-emetic effects of granisetron and palonosetron during the treatment of acute myeloid leukemia. Mol Clin Oncol 7: 629-632, 2017
APA
Matsumaru, A., Tsutsumi, Y., & Ito, S. (2017). Comparative investigation of the anti-emetic effects of granisetron and palonosetron during the treatment of acute myeloid leukemia. Molecular and Clinical Oncology, 7, 629-632. https://doi.org/10.3892/mco.2017.1350
MLA
Matsumaru, A., Tsutsumi, Y., Ito, S."Comparative investigation of the anti-emetic effects of granisetron and palonosetron during the treatment of acute myeloid leukemia". Molecular and Clinical Oncology 7.4 (2017): 629-632.
Chicago
Matsumaru, A., Tsutsumi, Y., Ito, S."Comparative investigation of the anti-emetic effects of granisetron and palonosetron during the treatment of acute myeloid leukemia". Molecular and Clinical Oncology 7, no. 4 (2017): 629-632. https://doi.org/10.3892/mco.2017.1350